期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 178, 期 3, 页码 564-581出版社
WILEY
DOI: 10.1111/bph.15330
关键词
abdominal aortic aneurysm; inflammation; JAK; STAT signalling; oxidative stress; peptidomimetic; SOCS1; vascular biology
资金
- Spanish Ministry of Economy and Competitiveness (MINECO-FEDER) [SAF2015-63696-R]
- Ministry of Science and Innovation (MICINN-FEDER) [RTI2018-098788-BI00]
- Instituto de Salud Carlos III (ISCIII-FISFEDER) [DTS-2017/00203, PI17/01495, PI19/00128]
- Comunidad de Madrid: Complemento [II-CM S2017/BMD3673]
- La Caixa Foundation [HR17-00247]
- Spanish Society of Arteriosclerosis
This study demonstrates the therapeutic potential of a SOCS1-derived peptide (S1) in halting AAA progression by suppressing JAK/STAT-mediated inflammation and aortic dilation. S1 peptide can reduce the incidence of AAA and aortic dilation, degrade elastin, and have vasculo-protective effects.
Background and Purpose Abdominal aortic aneurysm (AAA) is a multifactorial disease characterized by chronic inflammation, oxidative stress and proteolytic activity in the aortic wall. Targeting JAK/signal transducer and activator of transcription (JAK/STAT) pathway is a promising strategy for chronic inflammatory diseases. We investigated the vasculo-protective role of suppressor of cytokine signalling-1 (SOCS1), the negative JAK/STAT regulator, in experimental AAA. Experimental Approach A synthetic, cell permeable peptide (S1) mimic of SOCS1 kinase inhibitory domain to suppress STAT activation was evaluated in the well-established mouse model of elastase-induced AAA by monitoring changes in aortic diameter, cellular composition and gene expression in abdominal aorta. S1 function was further evaluated in cultured vascular smooth muscle cells (VSMC) and macrophages exposed to elastase or elastin-derived peptides. Key Results S1 peptide prevented AAA development, evidenced by reduced incidence of AAA, aortic dilation and elastin degradation, partial restoration of medial VSMC and decreased inflammatory cells and oxidative stress in AAA tissue. Mechanistically, S1 suppressed STAT1/3 activation in aorta, down-regulated cytokines, metalloproteinases and altered the expression of cell differentiation markers by favouring anti-inflammatory M2 macrophage and contractile VSMC phenotypes. In vitro, S1 suppressed the expression of inflammatory and oxidative genes, reduced cell migration and reversed the phenotypic switch of macrophages and VSMC. By contrast, SOCS1 silencing promoted inflammatory response. Conclusion and Implications This preclinical study demonstrates the therapeutic potential of SOCS1-derived peptide to halt AAA progression by suppressing JAK/STAT-mediated inflammation and aortic dilation. S1 peptide may therefore be a valuable option for the treatment of AAA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据